Press Release Details
Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service
Clonally perfect genes shipped in as few as five business days
Launch of ‘fast genes’ enabled by state-of-the-art Wilsonville manufacturing facility
“Twist Express Genes is our first new offering enabled by the increased capacity and streamlined processes in our Wilsonville facility. We are now able to deliver the same NGS-verified clonally perfect genes that our customers have come to expect from Twist in about half the time, at an unprecedented scale. We offer the rapid turnaround that our customers need in multiple formats and at the same speed for one or thousands of genes. With this new offering, we will focus initially on our current customers who we know are making some of their own genes,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Twist leverages its ability to miniaturize the chemical reaction to creating DNA using its silicon-based DNA synthesis platform along with expertise, software, honed processes and the expanded layout of its Wilsonville facility to deliver clonal genes and gene fragments at scale and with rapid turnaround times. Twist will utilize dynamic pricing for Express Genes, charging a premium price for speed, which will be determined by market demand and manufacturing capacity. Customers will be able to place orders for Express Genes through Twist’s ecommerce platform.
“We surveyed several hundred gene users and found that in addition to those who make their own genes entirely, a large portion of respondents both purchase DNA from a supplier and in parallel make their own,” said
"As a gene therapy startup developing programmable RNA medicines, we routinely generate diverse and customized DNA sequences to advance our technologies and enable application to multiple disease targets. Being able to order sequence-verified large synthetic gene constructs in just one week expands what we can screen and allows faster iterations of the design-build-test cycle," said
Twist Express Genes
Twist Express Genes are 0.3 to 5.0kb in length. Due to scale enabled by Twist’s platform, orders of any size both small and large can be filled, and as with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate. Twist Express Genes can be cloned into catalog vectors or custom vectors so that customers can move right to experimentation. They can also be shipped in customers’ preferred delivery formats, including tube and plate.
Current turnaround times for some
- Express Genes: order to shipping starting at 5 business days
- Standard speed Clonal Genes: starting at 10 business days
- Gene Fragments: starting at 2 business days with an error rate of 1:7,5003
- Oligo Pools up to 300nt: starting at 3 business days with an error rate of 1:3,0004
Twist quantified the minimal carbon footprint of manufacturing a single gene in its 2023 ESG report. View the report here: https://www.twistbioscience.com/company/esg?tab=environmental
1Express Genes ship in 5-7 business days. This time will vary based on complexity and length of the sequence. Orders placed outside of the US may incur additional delivery turnaround time.
2Research funded by
3Error rate from https://www.twistbioscience.com/products/genes?tab=fragment
4Error rate from https://www.twistbioscience.com/products/oligopools?tab=oligo-pools
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including statements regarding the turnaround time of the Twist Express Gene product, and Twist’s ability to service researchers currently making their own genes, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s workforce reduction and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products
SVP, Corporate Affairs